NSEI:GSKCONS

Stock Analysis Report

GlaxoSmithKline Consumer Healthcare

Executive Summary

GlaxoSmithKline Consumer Healthcare Limited manufactures and sells malt based foods, protein rich foods, and cereal based beverages in India.

Snowflake

Fundamentals

Flawless balance sheet with outstanding track record and pays a dividend.


Similar Companies

Share Price & News

How has GlaxoSmithKline Consumer Healthcare's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.4%

GSKCONS

3.9%

IN Food

3.3%

IN Market


1 Year Return

30.3%

GSKCONS

18.8%

IN Food

7.1%

IN Market

Return vs Industry: GSKCONS exceeded the Indian Food industry which returned 18.8% over the past year.

Return vs Market: GSKCONS exceeded the Indian Market which returned 7.1% over the past year.


Shareholder returns

GSKCONSIndustryMarket
7 Day3.4%3.9%3.3%
30 Day7.3%6.7%2.9%
90 Day20.8%17.3%3.1%
1 Year32.1%30.3%20.3%18.8%9.4%7.1%
3 Year54.0%48.2%70.2%65.2%22.7%16.4%
5 Year81.5%71.2%142.2%130.7%44.0%30.4%

Price Volatility Vs. Market

How volatile is GlaxoSmithKline Consumer Healthcare's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GlaxoSmithKline Consumer Healthcare undervalued compared to its fair value and its price relative to the market?

36.89x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: GSKCONS (₹9050.4) is trading above our estimate of fair value (₹2717.37)

Significantly Below Fair Value: GSKCONS is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: GSKCONS is poor value based on its PE Ratio (36.9x) compared to the Food industry average (14.3x).

PE vs Market: GSKCONS is poor value based on its PE Ratio (36.9x) compared to the Indian market (13x).


Price to Earnings Growth Ratio

PEG Ratio: GSKCONS is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: GSKCONS is overvalued based on its PB Ratio (9.3x) compared to the IN Food industry average (1x).


Next Steps

Future Growth

How is GlaxoSmithKline Consumer Healthcare forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

12.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: GSKCONS's forecast earnings growth (12.1% per year) is above the savings rate (7.6%).

Earnings vs Market: GSKCONS's earnings (12.1% per year) are forecast to grow slower than the Indian market (18.3% per year).

High Growth Earnings: GSKCONS's earnings are forecast to grow, but not significantly.

Revenue vs Market: GSKCONS's revenue (9.7% per year) is forecast to grow slower than the Indian market (11.3% per year).

High Growth Revenue: GSKCONS's revenue (9.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: GSKCONS's Return on Equity is forecast to be high in 3 years time (24.7%)


Next Steps

Past Performance

How has GlaxoSmithKline Consumer Healthcare performed over the past 5 years?

10.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: GSKCONS's earnings have grown by 10.7% per year over the past 5 years.

Accelerating Growth: GSKCONS's earnings growth over the past year (34.1%) exceeds its 5-year average (10.7% per year).

Earnings vs Industry: GSKCONS earnings growth over the past year (34.1%) exceeded the Food industry 15.6%.


Return on Equity

High ROE: GSKCONS's Return on Equity (25.2%) is considered high.


Return on Assets

ROA vs Industry: GSKCONS has a higher Return on Assets than the Food industry average last year.


Return on Capital Employed

ROCE Improving: GSKCONS has improved its Return on Capital Employed over the past 3 years.


Next Steps

Financial Health

How is GlaxoSmithKline Consumer Healthcare's financial position?


Financial Position Analysis

Short Term Liabilities: GSKCONS's short term assets (₹52.7B) exceeds its short term liabilities (₹18.1B)

Long Term Liabilities: GSKCONS's short term assets (52.7B) exceeds its long term liabilities (1.6B)


Debt to Equity History and Analysis

Debt Level: GSKCONS is debt free.

Reducing Debt: GSKCONS had no debt 5 years ago.

Debt Coverage: GSKCONS has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: GSKCONS has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Inventory Level: GSKCONS has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if GSKCONS's debt is covered by short term assets.


Next Steps

Dividend

What is GlaxoSmithKline Consumer Healthcare's current dividend yield, its reliability and sustainability?

1.16%

Current Dividend Yield


Dividend Yield vs Market

company1.2%marketbottom25%0.6%markettop25%2.4%industryaverage0.8%forecastin3Years1.4%

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: GSKCONS's dividend (1.16%) is higher than the bottom 25% of dividend payers in the Indian market (0.6%).

High Dividend: GSKCONS's dividend (1.16%) is low compared to the top 25% of dividend payers in the Indian market (2.42%).

Stable Dividend: GSKCONS's dividends per share have been stable in the past 10 years.

Growing Dividend: GSKCONS's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonably low payout ratio (42.9%), GSKCONS's dividend payments are well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.


Next Steps

Management

What is the CEO of GlaxoSmithKline Consumer Healthcare's salary, the management and board of directors tenure and is there insider trading?

3.0yrs

Average management tenure


CEO

Navneet Saluja 0

1.8yrs

Tenure

₹111,305,833

Compensation

Mr. Navneet Saluja is India Sub-Continent, Area General Manager and Managing Director and Director at GlaxoSmithKline Consumer Healthcare Limited since January 1, 2018. He has multi sectoral experience inc ...


CEO Compensation Analysis

Compensation vs. Market: Navneet has recently become CEO, making it difficult to compare their total compensation against companies of similar size in the Indian market.

Compensation vs Earnings: Navneet's compensation has increased by more than 20% in the past year.


Management Age and Tenure

3.0yrs

Average Tenure

Experienced Management: GSKCONS's management team is considered experienced (3 years average tenure).


Board Age and Tenure

1.5yrs

Average Tenure

63yo

Average Age

Experienced Board: GSKCONS's board of directors are not considered experienced ( 1.5 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Surinder Kumar (62yo)

    Director of Legal

    • Tenure: 0yrs
    • Compensation: ₹3.20m
  • Navneet Saluja

    ISC Area GM

    • Tenure: 1.8yrs
    • Compensation: ₹111.31m
  • Narendra Vutla

    Head of Product Optimization Center of Excellence

    • Tenure: 0yrs
  • Deepa Dey

    Head of Communications - ISC

    • Tenure: 6.8yrs
  • Sridhar Kameshwaran

    Executive Vice President of R&D International

    • Tenure: 4.3yrs
  • Shanu Saksena

    Company Secretary and Area Ethics & Compliance Officer

    • Tenure: 3.2yrs
    • Compensation: ₹15.55m
  • Anup Dhingra (52yo)

    Director of Operations & Executive Director

    • Tenure: 3.1yrs
    • Compensation: ₹64.78m
  • Arun Mishra

    Executive VP & Head of Regulatory Affairs - ISC

    • Tenure: 3.6yrs
  • Sanjeev Khanna

    Executive Vice President of Field Sales - India

    • Tenure: 2.6yrs
  • Rahul Kapoor

    Executive Vice President of Human Resources

    • Tenure: 1.3yrs

Board Members

  • Sangeeta Talwar (63yo)

    Independent Director

    • Tenure: 5.2yrs
    • Compensation: ₹2.50m
  • Patnam Dwarakanath (72yo)

    Non-Executive Chairman

    • Tenure: 1.3yrs
    • Compensation: ₹2.23m
  • Navneet Saluja

    ISC Area GM

    • Tenure: 1.8yrs
    • Compensation: ₹111.31m
  • Pradeep Bhide (69yo)

    Independent Director

    • Tenure: 0.4yrs
  • Subramanian Madhavan (63yo)

    Additional Independent Director

    • Tenure: 1.1yrs
    • Compensation: ₹550.00k
  • Anup Dhingra (52yo)

    Director of Operations & Executive Director

    • Tenure: 3.1yrs
    • Compensation: ₹64.78m

Company Information

GlaxoSmithKline Consumer Healthcare Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GlaxoSmithKline Consumer Healthcare Limited
  • Ticker: GSKCONS
  • Exchange: NSEI
  • Founded: 1958
  • Industry: Packaged Foods and Meats
  • Sector: Food, Beverage & Tobacco
  • Market Cap: ₹380.167b
  • Shares outstanding: 42.06m
  • Website: https://india-consumer.gsk.com

Number of Employees


Location

  • GlaxoSmithKline Consumer Healthcare Limited
  • One Horizon Centre
  • 24-25 Floor
  • Gurugram
  • Haryana
  • 122002
  • India

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
500676BSE (Mumbai Stock Exchange)YesEquity SharesININRApr 1999
GSKCONSNSEI (National Stock Exchange of India)YesEquity SharesININRApr 1999

Biography

GlaxoSmithKline Consumer Healthcare Limited manufactures and sells malt based foods, protein rich foods, and cereal based beverages in India. The company offers health food drinks and biscuits under the Ho ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/22 12:43
End of Day Share Price2019/10/22 00:00
Earnings2019/06/30
Annual Earnings2019/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.